The UK regulator, the MHRA, is to introduce a new accelerated licensing procedure for innovative medicines from the beginning of 2021, when it is due to assume full responsibility for marketing authorizations and related regulatory activities as a result of the country's departure from the EU.
The agency will have a closer focus on patient access to highly innovative products, and more use will be made...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?